Will Spiraling Costs Retard Growth Of Clinical Research In India? The Jury Is Out
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - From being a preferred destination for conducting clinical research to facing competitive pressure from countries like Malaysia, the Indian clinical research industry may miss the opportunity of emerging as a global hub for multinational drug companies
You may also be interested in...
Launching Clinical Trials In India? Beware Of Long Delays And New Mandates
MUMBAI - Inordinate delays in the approval process for clinical trials may be dissuading sponsors and CROs from considering India as part of their upcoming global programs
Launching Clinical Trials In India? Beware Of Long Delays And New Mandates
MUMBAI - Inordinate delays in the approval process for clinical trials may be dissuading sponsors and CROs from considering India as part of their upcoming global programs
Top Indian CROs Unite On Centralized Biometric Database Covering Trial Volunteers
MUMBAI - Leading Indian clinical research organizations have united to create a centralized biometrics database in what is seen as the first ever concerted attempt to avoid duplication of volunteers in various clinical trials within the "wash-out period.